Table 1 Characteristics and outcome of patients treated with brachytherapy
Characteristics | Initial Cohort n = 296 (100%) | |
|---|---|---|
Gleason Score | ≤ 6 | 173 (58.4%) |
> 6 | 32 (10.8%) | |
Unknown | 91 (30.7%) | |
Preoperative PSA value | ≤ 10 ng/ml | 208 (70.3%) |
> 10 (−20) ng/ml | 62 (20.9%) | |
> 20 ng/ml | 26 (8.8%) | |
Risk groupa | Low | 110 (37.1%) |
Intermediate | 26 (8.8%) | |
High | 52 (17.6%) | |
Unknown | 90 (30.4%) | |
T3 (n = 15), N1 (n = 2), or M1 (n = 1) | 18 (6.1%) | |
Endpoint | Clinical outcome | Number of Patients (Percentage) |
All patients | 296 (100%) | |
Overall survival in all (n = 296) patients | Died before 2004 (Original cohort) Died between 2004 and 2013 (Current cohort) | 38 (12.8%) 32 (10.8%) |
Unknown Alive but not willing to participate Alive and contacted by phone No available contact information but alive; clinical information as reported by urologist or general practitioner | 100 (33.8%) 6 (2%) 114 (38.5%) 6 (2%) | |
All deaths | 70 (100%) | |
Causes of death in 70 patients who had died. | Prostate carcinoma Unrelated cancer Leukemia Gastric cancer Pancreatic cancer Lung cancer Cardiovascularb Infectionc Kidney failure Other or unknown | 20 (28.6%) 8 (11.4%) 2 1 3 2 16 (22.9%) 3 (4.3%) 3 (4.3%) 20 (28.6%) |
Patients contacted | 120 (100%) | |
Biochemical recurrence at any time in n = 120 patients with clinical information who were alive at final follow-up | Biochemical recurrence present at any time | 22 (18.3%) |
No biochemical recurrence | 68 (56.7%) | |
Unknown biochemical outcome | 30 (25%) | |
All patients with biochemical recurrence | 22 (100%) | |
Clinical recurrence in patients who are alive and had biochemical recurrence | Local recurrence at any time Distant metastases at any time Distant and local recurrence Unknown | 10 (45.4%) 2 (9.1%) 1 (4.5%) 13 (59.1%) |